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AbsTrACT
background Hyperprolactinaemia is a common 
antipsychotic (AP)-induced adverse effect, particularly in 
female patients.
Aims This meta-analysis examined the efficacy and 
safety of adjunctive aripiprazole in preventing AP-related 
hyperprolactinaemia in patients with first-episode 
schizophrenia.
Methods PubMed, PsycINFO, EMBASE, Cochrane 
Library, WanFang and China Journal Net databases were 
searched to identify eligible randomised controlled trials 
(RCTs). Primary outcomes were the reductions of serum 
prolactin level and prolactin-related symptoms. Data 
were independently extracted by two reviewers and 
analysed using RevMan (V.5.3). Weighted/standardised 
mean differences (WMDs/SMDs)±95% CIs were 
reported.
results In the five RCTs (n=400), the adjunctive 
aripiprazole (n=197) and the control groups (n=203) 
with a mean of 11.2 weeks of treatment duration were 
compared. The aripiprazole group had a significantly 
lower endpoint serum prolactin level in all patients (five 
RCTs, n=385; WMD: −50.43 ng/mL (95% CI: −75.05 
to −25.81), p<0.00001; I2=99%), female patients (two 
RCTs, n=186; WMD: −22.58 ng/mL (95% CI: −25.67 to 
−19.49), p<0.00001; I2=0%) and male patients (two RCTs, 
n=127; WMD: −68.80 ng/mL (95% CI: −100.11 to −37.49), 
p<0.0001). In the sensitivity analysis for the endpoint 
serum prolactin level in all patients, the findings remained 
significant (p<0.00001; I2=96%). The aripiprazole group 
was superior to the control group in improving negative 
symptoms as assessed by the Positive and Negative 
Syndrome Scale (three RCTs, n=213; SMD: −0.51 (95% 
CI: −0.79 to −0.24), p=0.0002; I2=0%). Adverse effects 
and discontinuation rates were similar between the two 
groups.
Conclusions Adjunctive aripiprazole appears to be 
associated with reduced AP-induced hyperprolactinaemia 
and improved prolactin-related symptoms in first-episode 
schizophrenia. Further studies with large sample sizes are 
needed to confirm these findings.
InTroduCTIon
Hyperprolactinaemia caused by antipsy-
chotics (APs) is a serious and unwanted 
adverse effect in patients with schizo-
phrenia.1 2 With the rates up to 86%,3 it is 
closely related to the dopamine D2 receptor 
gene Taq1A genotype.4
There have been several treatment strat-
egies recommended to prevent or alleviate 
hyperprolactinaemia in clinical practice 
although some remain controversial because 
(1) the use of the lowest effective AP dose may 
increase the risk of relapse during mainte-
nance treatments;5 (2) switching to other APs 
with a lower risk of hyperprolactinaemia could 
be associated with some other adverse effects, 
such as sedation and metabolic syndrome;6 
(3) adding a dopamine agonist, such as caber-
goline, may result in abnormal involuntary 
movements and aggravated psychosis;7 8 (4) 
the use of metformin, which may bring bene-
fits to some hyperprolactinaemic patients,9 10 
may be associated with gastrointestinal reac-
tions;11 and (5) the evidence for the use of 
paeoniae–glycyrrhiza decoction, a herbal 
medicine formula consisting of paeonia and 
glycyrrhiza radices (Shaoyao-Gancao-Tang 
in Chinese and Shakuyaku-Kanzo-To in Japa-
nese, TJ-68), is still lacking.7 12–14
Emerging evidence has found that aripipra-
zole, a partial agonist of dopamine D2 recep-
tors,15 16 could effectively reduce prolactin 
level and increase the rate of prolactin 
normalisation, and even improve prolac-
tin-related symptoms in patients with AP-re-
lated hyperprolactinaemia.2 17 18 In addition, 
it would appear that adjunctive aripiprazole is 
one of the safest strategies to improve hyper-
prolactinaemia induced by APs.19
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To date, several randomised controlled trials (RCTs)20–24 
of aripiprazole as an adjunct treatment for AP-induced 
hyperprolactinaemia have been conducted in first-ep-
isode patients with schizophrenia, but the results are 
inconsistent. An earlier meta-analysis focusing on both 
patients with first-episode and chronic schizophrenia 
found superiority of adjunctive aripiprazole over placebo 
in the improvement of AP-related hyperprolactinaemia.18 
To date, however, no meta-analysis or systematic review 
exclusively examining the effect of adjunctive aripiprazole 
in preventing AP-related hyperprolactinaemia in first-ep-
isode schizophrenia was published. We thus conducted 
this meta-analysis of RCTs in patients with first-episode 
schizophrenia to evaluate the efficacy and safety of arip-
iprazole as an additional treatment for hyperprolacti-
naemia induced by AP.
MeThods
Types of studies
Based on the PICOS acronym as recommended by the 
previous meta-analyses25 26, the following selection criteria 
of this meta-analysis were presented: Participants (P): 
adult patients (without restriction in setting, gender and 
ethnicity) with first-episode schizophrenia based on any 
diagnostic criteria. First episode was defined as first onset 
of psychotic symptoms. Intervention (I): the combination 
of APs and aripiprazole. Comparison (C): the combina-
tion of APs and placebo or AP monotherapy. Outcomes 
(O): the primary outcome was the reduction of serum 
prolactin level; key secondary outcomes included (1) the 
improvement of prolactin-related symptoms (oligomen-
orrhoea, amenorrhoea and galactorrhoea recovery), (2) 
improvement of psychotic symptoms as assessed by the 
Positive and Negative Syndrome Scale (PANSS)27 or the 
Brief Psychiatric Rating Scale (BPRS),28 (3) tolerability 
and safety: discontinuation rate and adverse effects as 
assessed by the Treatment Emergent Symptom Scale.29 
Study design (S): RCTs (no restriction in treatment dura-
tion) reporting prolactin-related symptoms or serum 
prolactin levels with meta-analysable data. We excluded 
observational studies, case reports/series, conference arti-
cles, non-randomised studies, animal studies, meta-anal-
yses and systematic reviews.
study selection
A systematic search, in line with the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses (PRISMA) statement,30 was performed in English 
(PubMed, EMBASE, PsycINFO, Cochrane Library data-
bases) and Chinese databases (WanFang and China 
Journal Net databases) for RCTs evaluating adjunctive 
aripiprazole for hyperprolactinaemia induced by AP 
in patients with first-episode schizophrenia from incep-
tion to 1 July 2019. The keywords used for the searches 
included (aripiprazole OR abilify) AND (hyperprolac-
tinemia OR gynecomastia OR galactorrhea OR amen-
orrhea OR oligomenorrhea OR menstrual irregularities 
OR prolactin) AND (schizoaffective disorder OR schizo-
phreniform OR Schizophrenic Disorder OR Disorder, 
Schizophrenic OR Schizophrenic Disorders OR Schizo-
phrenia OR Dementia Praecox) AND (first episode OR 
early phase OR early-phase OR treatment-naïve OR naïve 
OR untreated OR undiagnosed OR first diagnosed OR 
first diagnosis). The bibliographies of published relevant 
reviews or meta-analyses2 18 also were hand-searched for 
additional studies.
data extraction
Two independent reviewers identified, checked and 
extracted data of the included studies. Inconsistencies 
were resolved by consensus involving a third reviewer. 
If the same data were reported in more than one RCT, 
only the RCT with complete data was included for anal-
yses. Authors were contacted by email in order to obtain 
missing or more information if necessary.
statistical methods
All meta-analytic data were performed using RevMan 
(V.5.3) (http://www. cochrane. org) following the recom-
mendations of the Cochrane Collaboration. A random-ef-
fect model31 was used in all cases due to heterogeneity 
in methodology, treatment duration, study size, sampling 
and doses of aripiprazole. For dichotomous and contin-
uous outcomes, risk ratios and weighted and standardised 
mean differences (WMDs/SMDs) with their 95% CIs 
were reported, respectively. There was a heterogeneous 
result for meta-analytic data when I2 values were greater 
than 50% or p value <0.1 in the Q statistics.32 For primary 
outcomes, we sought reasons for heterogeneity by 
conducting a sensitivity analysis by removing two outlying 
(SMD <−5.0) studies.20 22 Publication bias was assessed 
using the funnel plots and Egger's Regression Intercept.33 
All analyses were two tailed, with the significance level set 
at 0.05.
Assessment of study quality
The quality of included RCTs were independently assessed 
by two reviewers (X-HY and D-BC) using Cochrane risk 
of bias.34 Following the methodology of other studies,35 36 
the Jadad scale37 was also used to assess the quality of each 
study. Furthermore, the criteria of high and low quality of 
the included studies were defined as Jadad scores ≥3 and 
<3, respectively.35 36 Additionally, the quality of overall 
evidence of primary and secondary outcome measures 
of adjunctive aripiprazole for hyperprolactinaemia was 
assessed using the grading of recommendations assess-
ment, development and evaluation (GRADE) system.38 39
resulTs
results of the search
A total of 872 potentially relevant articles in the initial 
database search (870 trials) and other sources (two trials) 
were ascertained (figure 1). After removing duplicate 
articles (156 trials), and reading the titles or abstracts 
3Zheng W, et al. General Psychiatry 2019;32:e100091. doi:10.1136/gpsych-2019-100091
General Psychiatry
Figure 1 PRISMA flowchart. RCT, randomised controlled 
trial.
(694 trials) and reviewing full texts (17 trials), finally, five 
RCTs were eligible and analysed.
study characteristics
All five RCTs (n=400) included double-blinded (one 
RCT, n=80), single-blinded (one RCT, n=72) and open-
label trials (three RCTs, n=248) and compared the 
adjunctive aripiprazole (n=197) and the control groups 
(n=203). The mean of the treatment duration was 11.2 
weeks (range, 8–24 weeks) (table 1). All included RCTs 
were conducted in China.
Patient characteristics
Only two RCTs20 23 reported mean age with 36.7 years 
(range, 30.5–42.9 years) (table 1). The percentage of 
men was 50% (range, 0%–100%) in four RCTs with avail-
able data,20 21 23 24 and illness duration was 15.3 (range, 
4.5–26) months in two RCTs with available data.20 23
Treatment characteristics
The mean dosage of aripiprazole dosage was 7.5 mg/day 
(range, 2.5–10 mg/day) in four RCTs with available data. 
Furthermore, baseline APs included amisulpride (one 
RCT), olanzapine (one RCT), risperidone (two RCTs) 
and sulpiride (one RCT).
Quality assessment
Three RCTs reported randomisation methods with a 
specific description and the remaining were rated as 
unclear (online supplementary figure 1). The Jadad score 
ranged from 1 to 4 (mean=2.6) (table 1). Two studies 
(40%) were classified as low quality and the others were 
high quality (60%), respectively. The quality of evidence 
presented for nine outcome measures, based on the 
GRADE approach, ranged from ‘very low’ (12.5%), ‘low’ 
(50.0%) to ‘moderate’ (37.5%) (online supplementary 
table 1).
Treatment efficacy
The aripiprazole group had a significantly lower 
endpoint serum prolactin level in all patients (five RCTs, 
n=385; WMD: −50.43 ng/mL (95% CI: −75.05 to −25.81), 
p<0.00001; I2=99%, figure 2), in female patients (two 
RCTs, n=186; WMD: −22.58 ng/mL (95% CI: −25.67 to 
−19.49), p<0.00001; I2=0%, figure 2) and in male patients 
(two RCTs, n=127; WMD: −68.80 ng/mL (95% CI: −100.11 
to −37.49), p<0.0001, figure 2) when compared with the 
control group.
The results remained significant after removing two 
outlying studies20 22 regarding endpoint serum prolactin 
level in all patients (three RCTs, n=248; WMD: −39.39 ng/
mL (95% CI: −56.63 to −22.15), p<0.00001; I2=96%).
Due to the limited number of RCTs, subgroup and 
meta-regression analyses, and publication bias could not 
be examined.
Psychiatric symptoms
Meta-analyses of PANSS negative symptoms (three RCTs, 
n=213; SMD: −0.51 (95% CI: −0.79 to −0.24), p=0.00002; 
I2=0%, figure 3) showed a significant superiority of the 
adjunctive aripiprazole group over the control group. 
However, meta-analyses of total scores of PANSS (four 
RCTs) and BPRS (one RCT) (five RCTs, n=385; SMD: 
−0.32 (95% CI: −0.64 to 0.00), p=0.05; I2=60%, figure 3) 
and PANSS positive symptoms (three RCTs, n=213; SMD: 
−0.08 (95% CI: −0.58 to 0.43), p=0.76; I2=71%, figure 3) 
did not show significant differences between the aripipra-
zole and the control groups.
Adverse effects and discontinuation rates
Three RCTs reported adverse effects (table 2). Meta-anal-
yses of any extrapyramidal symptoms (p=0.84, online 
supplementary figure 2) did not show significant differ-
ences between the two groups. Prolactin-related symptoms 
(such as amenorrhoea, oligomenorrhoea and galactor-
rhoea) were significantly more frequent in the control 
group compared with the aripiprazole group (table 2). 
However, nine female patients reported galactorrhoea 
and seven male patients reported gynecomastia in the 
aripiprazole group, while no female or male patients 
reported these two outcomes in the control group in one 
RCT. Other adverse effects did not significantly differ 
between the two groups (table 2).
Meta-analyses of all caused discontinuation did not 
show significant differences between the two groups 
(p=0.47, online supplementary figure 2).
dIsCussIon
Main findings
To the best of our knowledge, this was the first 
meta-analysis of RCTs that examined the efficacy 
and safety of adjunctive aripiprazole for AP-related 
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Figure 2 Adjunctive aripiprzaole for antipsychotic-induced hyperprolactinaemia: forest plot for the serum prolactin level (ng/
mL) and body weight (kg) at endpoint.
Figure 3 Adjunctive aripiprazole for antipsychotic-induced hyperprolactinaemia: forest plot for total psychopathology 
assessed by the Positive and Negative Syndrome Scale (PANSS) and the Brief Psychiatric Rating Scale, PANSS positive 
symptom and negative symptom at endpoint.
hyperprolactinaemia in patients with first-episode 
schizophrenia. The findings suggest that adjunctive 
aripiprazole could significantly reduce the level of 
elevated prolactin and improve prolactin-related 
symptoms. This adjunctive strategy appears to be safe, 
well-tolerated and associated with improved negative 
symptoms. Given that the overall quality level was rated 
as ‘low’ in reducing the level of elevated prolactin and 
improving negative symptoms, these findings need to 
be interpreted with caution.
limitations
The study has several limitations. First, the sample sizes 
were relatively small (n=400) in the five RCTs, which 
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Table 2 Adjunctive aripiprazole for antipsychotic-related hyperprolactinaemia: ADRs
Secondary outcome Study
Control group Aripiprazole group
FindingsTotal (n) Events (n) Total (n) Events (n)
Prolactin-related symptom* Zhou et al 201424 50 28 50 4 p<0.05
Any extrapyramidal related with adverse effect† Zhou et al 201424 50 22 50 24 NS
Galactorrhoea (female) Ren and Hu 201122 16 9 NR 0 NA
Gynecomastia (male) Ren and Hu 201122 20 7 NR 0 NA
Akathisia Ren and Hu 201122 36 0 36 1 NS
Any extrapyramidal related with adverse effect Ren and Hu 201122 36 2 36 0 NS
Insomnia Ren and Hu 201122 36 0 36 2 NS
Tremor Chen et al 200920 40 4 40 4 NS
Dry mouth Chen et al 200920 40 3 40 3 NS
ECG abnormality Chen et al 200920 40 4 40 3 NS
Dizziness Chen et al 200920 40 3 40 2 NS
Tachycardia Chen et al 200920 40 6 40 8 NS
Anxiety Chen et al 200920 40 5 40 4 NS
Constipation Chen et al 200920 40 4 40 6 NS
Elevated liver enzymes Chen et al 200920 40 6 40 5 NS
Hypersalivation Chen et al 200920 40 6 40 8 NS
Hyperglycaemia Chen et al 200920 40 2 40 3 NS
*Included amenorrhoea, oligomenorrhoea, galactorrhoea, etc.
†Included akathisia, tremor, oculogyric crisis, etc.
ADR, adverse drug reaction; NA, not applicable; NR, not reported; NS, not significant.
hinders the ability to conduct more comprehensive data 
analyses, such as subgroup and meta-regression anal-
yses. Second, three RCTs were classified as high quality 
using the Jadad scale37 and three RCTs reported rando-
misation methods with a specific description using the 
Cochrane risk of bias,34 but the quality of 50% of the 
overall evidence was classified as ‘low’ quality based 
on the GRADE approach.38 39 However, low-quality 
evidence could still result in strong recommendations 
according to Guyatt et al’s suggestion.40 Third, the 
significant heterogeneity (I2>50%) of meta-analytic 
results of serum prolactin level in the whole sample 
may be attributed to different methodology, study sizes, 
sampling, antipsychotic doses and treatment duration 
across studies. However, the results remained the same 
after a sensitivity analysis by removing two outlying 
studies was conducted. Finally, all included studies were 
conducted in China and published in Chinese. There-
fore, the findings of the current study warrant confir-
mation in other countries.
Implications
APs, such as haloperidol or risperidone, increase 
prolactin secretion through dopamine-blocking actions 
in the tuberoinfundibular system.41 Antagonist activity 
at D2 receptors in the tuberoinfundibular system 
region reduces dopamine activity and then increases 
the risk of hyperprolactinaemia.2 In contrast, aripipra-
zole is a partial dopamine agonist in conditions of low 
endogenous dopamine activity15 and could suppress the 
elevated serum prolactin level by preventing the devel-
opment of hypodopaminergia in the tuberoinfundib-
ular system .2
Aripiprazole dose–response effects in reducing the 
elevated prolactin level could not be analysed in this 
meta-analysis because the aripiprazole mean doses 
(7.5 mg/day) were only provided in four RCTs. A prior 
meta-analysis2 of five RCTs (n=663) suggested aripip-
razole less than 5 mg/day could significantly decrease 
prolactin levels in patients with chronic schizophrenia. 
In addition, 2 mg/day of aripiprazole could act as a 
partial dopamine agonist and showed improvement of 
prolactin-related symptoms.42 43 Thus, a dose of 5 mg/
day appears to be a reasonable target dose for aripip-
razole for AP-related hyperprolactinaemia in patients 
with first-episode schizophrenia, but further studies are 
needed to explore the optimal dose range.
Apart from its efficacy in reducing the elevated 
prolactin level, adjunctive aripiprazole could signifi-
cantly improve negative symptoms, which is consistent 
with a recent published meta-analysis.18
ConClusIons
This meta-analysis of RCTs showed that adjunctive 
aripiprazole appears to be associated with reduced 
hyperprolactinaemia induced by AP and improved 
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prolactin-related symptoms in first-episode schizo-
phrenia, which has important clinical implications for 
reducing the risk of AP-related hyperprolactinaemia. It 
may also improve prolactin-related symptoms without 
associated increase in adverse effects and discontin-
uation rates. RCTs with a larger sample size on arip-
iprazole for hyperprolactinaemia induced by APs in 
patients with first-episode schizophrenia are needed in 
the future.
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